Every 8-K that Doximity, Inc. (DOCS) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow DOCS and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full DOCS filings page.
Doximity, Inc. (DOCS) reported the results of its 2026 Annual Meeting of Stockholders held on August 27, 2026. Common stockholders representing 614,551,986 votes, or 96.34% of votes entitled to be cast, were present in person or by proxy, constituting a quorum. Stockholders elected Class II directors Kevin Spain and Timothy Cabral to serve until the 2029 annual meeting, with Spain receiving 534,599,583 votes for and Cabral 587,108,878 votes for. Stockholders also ratified Deloitte & Touche LLP as independent registered public accounting firm for the fiscal year ending March 31, 2027, with 610,837,373 votes for. In a non-binding advisory vote, stockholders approved executive compensation for the fiscal year ended March 31, 2026, with 555,836,605 votes for and 33,841,608 against.
Doximity reported fiscal 2027 first‑quarter results with revenue of $156.6 million, up 7% year‑over‑year. Net income was $24.3 million with a 15.5% margin, down from $53.3 million and 36.5% a year earlier. Adjusted EBITDA was $74.8 million with a 47.7% margin.
GAAP gross margin was 84.9%, and non‑GAAP gross margin 87.5%. Operating cash flow was $42.0 million and free cash flow $39.6 million, both down more than 30% year‑over‑year. Cash and cash equivalents were $273.6 million and marketable securities $414.2 million as of June 30, 2026. The company repurchased $91.6 million of common stock in the quarter.
Management noted its Doximity Ask clinical AI assistant was the top‑performing U.S.-based model in the NOHARM benchmark and highlighted record engagement, with workflow active prescriber growth of more than 30% year‑over‑year and AI Search query growth of over 25% quarter‑over‑quarter. Doximity guides second‑quarter revenue to $170–$171 million and adjusted EBITDA to $80.5–$81.5 million, and full‑year revenue to $671–$681 million with adjusted EBITDA of $309–$329 million.
Doximity, Inc. reported fiscal year 2026 revenue of $644.9 million, up 13% from $570.4 million, with adjusted EBITDA rising to $357.8 million and free cash flow to $317.5 million, both up 14–19% year-over-year.
GAAP net income for the year declined to $196.1 million from $223.2 million as margins narrowed, though non-GAAP net income improved to $302.7 million. In Q4, revenue grew 5% to $145.4 million, while net income fell to $19.1 million, reflecting higher operating expenses and stock-based compensation. The company highlighted strong engagement, with over 800,000 active prescribers using workflow tools in Q4 and broad adoption of its clinical AI features.
For fiscal 2027, Doximity guides to revenue of $664–$676 million and adjusted EBITDA of $323–$335 million. The company also appointed Matthew Sonefeldt as Chief Financial Officer and Steven L. Zatz, M.D. as President, each with base salary of $400,000 and multi‑year RSU packages tied to time-based and performance-based vesting.
Doximity, Inc. announced that Chief Financial Officer Anna Bryson, who had been on medical leave since early February 2026, resigned from her role effective April 13, 2026. Chief Accounting Officer Siddharth Sitaram continues to serve as interim principal financial and accounting officer until a new CFO is appointed.
The company plans to give an update on its CFO search during its next earnings call. Doximity also reaffirmed its previously issued guidance for the fourth quarter and full fiscal year ending March 31, 2026, as first shared on February 5, 2026.
Doximity, Inc. reported that it issued a press release with financial results for its fiscal quarter ended December 31, 2025, and furnished that release as an exhibit. The company also announced that Chief Financial Officer and principal accounting officer Anna Bryson is taking a temporary medical leave. Effective February 3, 2026, Chief Accounting Officer Siddharth Sitaram was appointed interim principal financial officer and interim principal accounting officer, continuing a leadership team with deep internal experience at the company.
Doximity, Inc. reported that it has entered into an Agreement of Settlement to resolve a securities litigation case pending in the U.S. District Court for the Northern District of California. The proposed settlement calls for an aggregate payment of $31 million, which will be fully funded by insurance proceeds rather than by the company directly. If approved by the court and all conditions are met, all claims against Doximity and the named directors and officers will be dismissed without any admission of liability, fault or wrongdoing. The settlement is still subject to stockholder notice, court approval, and other customary conditions, and the company notes that appeals, opt-outs by individual plaintiffs, or issues with insurance carriers could affect the final outcome.
Doximity, Inc. filed an 8-K announcing it issued a press release with financial results for its fiscal quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 and is incorporated by reference.
The information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not subject to Section 18 liabilities, nor incorporated into other filings except as expressly referenced. The report was signed by Chief Financial Officer Anna Bryson.
Doximity, Inc. reported the results of its 2025 Annual Meeting of Stockholders held on August 28, 2025. Stockholders representing 97.51% of the voting power were present, providing a strong quorum for conducting company business.
Two Class I directors, Jeff Tangney and Kira Wampler, were elected to serve until the 2028 annual meeting. Stockholders also ratified Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending March 31, 2026. In addition, stockholders approved, on a non-binding advisory basis, the compensation of Doximity’s named executive officers for the fiscal year ended March 31, 2025.
Doximity, Inc. announced that its General Counsel, Corporate Secretary, and Chief Compliance Officer, Jennifer Chaloemtiarana, will step down from all three roles effective August 29, 2025, and John Vaughan will assume these positions on the same date.
Chaloemtiarana will continue with the company in an advisory capacity through November 17, 2025, after which she will receive post-employment payments and benefits under her August 10, 2020 offer letter referenced in a prior Form 10-Q filing.